← All trials
NCT04504825
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 25, 2020
- Primary completion
- Aug 2, 2022
- Completion date
- Feb 24, 2023
- First posted
- Aug 7, 2020
- Last posted
- Nov 27, 2020
- Enrollment
- 111
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fortress BiotechLead sponsor
- IQVIACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.